Cargando…

Irbesartan in Marfan syndrome (AIMS): a double-blind, placebo-controlled randomised trial

BACKGROUND: Irbesartan, a long acting selective angiotensin-1 receptor inhibitor, in Marfan syndrome might reduce aortic dilatation, which is associated with dissection and rupture. We aimed to determine the effects of irbesartan on the rate of aortic dilatation in children and adults with Marfan sy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mullen, Michael, Jin, Xu Yu, Child, Anne, Stuart, A Graham, Dodd, Matthew, Aragon-Martin, José Antonio, Gaze, David, Kiotsekoglou, Anatoli, Yuan, Li, Hu, Jiangting, Foley, Claire, Van Dyck, Laura, Knight, Rosemary, Clayton, Tim, Swan, Lorna, Thomson, John D R, Erdem, Guliz, Crossman, David, Flather, Marcus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6934233/ https://www.ncbi.nlm.nih.gov/pubmed/31836196 http://dx.doi.org/10.1016/S0140-6736(19)32518-8

Ejemplares similares

A prospective, randomized, placebo-controlled, double-blind, multicenter study of the effects of irbesartan on aortic dilatation in Marfan syndrome (AIMS trial): study protocol
por: Mullen, Michael J, et al.
Publicado: (2013)

Exaggerated elastin turnover in young individuals with Marfan syndrome: new insights from the AIMS trial
por: Iskandar, Zaid, et al.
Publicado: (2023)

Pectus updates and special considerations in Marfan syndrome
por: Fraser, Stephanie, et al.
Publicado: (2018)

Design and rationale of a prospective, collaborative meta-analysis of all randomized controlled trials of angiotensin receptor antagonists in Marfan syndrome, based on individual patient data: A report from the Marfan Treatment Trialists' Collaboration
por: Pitcher, Alex, et al.
Publicado: (2015)

Irbesartan in experimental diabetic nephropathy
por: Mahajan, Rajiv, et al.
Publicado: (2010)

Angiotensin receptor blockers and β blockers in Marfan syndrome: an individual patient data meta-analysis of randomised trials
por: Pitcher, Alex, et al.
Publicado: (2022)

Endothelial effects of antihypertensive treatment: focus on irbesartan
por: Negro, Roberto
Publicado: (2008)

Fixed combination of irbesartan and hydrochlorothiazide in the management of hypertension
por: Bramlage, Peter
Publicado: (2009)

Biochemical effects of irbesartan in experimental diabetic nephropathy
por: Vaishya, Richa, et al.
Publicado: (2009)

Gastrointestinal Symptoms in Marfan Syndrome and Hypermobile Ehlers-Danlos Syndrome
por: Inayet, N., et al.
Publicado: (2018)

Marfan Syndrome
por: Sivasankari, T, et al.
Publicado: (2017)

Marfan syndrome and the eye clinic: from diagnosis to management
por: Akram, Haseeb, et al.
Publicado: (2021)

Marfan syndrome and pregnancy: maternal and neonatal outcomes
por: Curry, RA, et al.
Publicado: (2014)

Long-term use and tolerability of irbesartan for control of hypertension
por: Forni, Valentina, et al.
Publicado: (2011)

Irbesartan improves arterial compliance more than lisinopril
por: Ali, Khalid, et al.
Publicado: (2009)

Comprehensive overview: efficacy, tolerability, and cost-effectiveness of irbesartan
por: Gialama, Fotini, et al.
Publicado: (2013)

Late-Onset Rash from Irbesartan: An Immunological Reaction
por: Cardoso, Bárbara Kong, et al.
Publicado: (2019)

Changes of Necroptosis in Irbesartan Medicated Cardioprotection in Diabetic Rats
por: Xu, Qingmei, et al.
Publicado: (2021)

A phenotypic screen of Marfan syndrome iPSC-derived vascular smooth muscle cells uncovers GSK3β as a new target
por: Davaapil, Hongorzul, et al.
Publicado: (2023)

Individual patient data meta-analysis of beta-blockers in heart failure: rationale and design
por: Kotecha, Dipak, et al.
Publicado: (2013)

Echocardiographic diagnosis of cardiac amyloidosis: Does the masquerader require only a "cherry on top"?
por: Kiotsekoglou, Anatoli, et al.
Publicado: (2020)

Irbesartan Induced Cutaneous Melanoma! Second Case in the Medical Literature!
por: Tchernev, Georgi, et al.
Publicado: (2019)

Development of binary dispersions and nanocomposites of irbesartan with enhanced antihypertensive activity
por: Puri, Vivek, et al.
Publicado: (2020)

The effect of solution environment and the electrostatic factor on the crystallisation of desmotropes of irbesartan
por: Araya-Sibaja, Andrea M., et al.
Publicado: (2019)

A Case of Sprue-like Enteropathy Associated With Valsartan and Irbesartan
por: Yoo, Seo Yeon, et al.
Publicado: (2022)

Clinical efficacy of linagliptin combined with irbesartan in patients with diabetic nephropathy
por: Liu, Jie, et al.
Publicado: (2022)

Ventricular‐Vascular Coupling in Marfan and Non‐Marfan Aortopathies
por: Loeper, Farina, et al.
Publicado: (2016)

Marfan's Syndrome
por: Bhatia, Tanuj, et al.
Publicado: (2012)

Marfan on the Move
por: de Waard, Vivian
Publicado: (2017)

Formulation and development of a self-nanoemulsifying drug delivery system of irbesartan
por: Patel, Jaydeep, et al.
Publicado: (2011)

Efficacy of Irbesartan on Left Ventricular Mass and Arterial Stiffness in Hypertensive Patients
por: Park, Chang Gyu, et al.
Publicado: (2006)

Effects of irbesartan on serum uric acid levels in patients with hypertension and diabetes
por: Nakamura, Makiko, et al.
Publicado: (2014)

Response to angiotensin blockade with irbesartan in a patient with metastatic colorectal cancer
por: Jones, M. R., et al.
Publicado: (2016)

Irbesartan desmotropes: Solid-state characterization, thermodynamic study and dissolution properties
por: Araya-Sibaja, Andrea Mariela, et al.
Publicado: (2019)

Long-Term Effects of Irbesartan Treatment and Smoking on Nucleic Acid Oxidation in Patients With Type 2 Diabetes and Microalbuminuria: An Irbesartan in Patients With Type 2 Diabetes and Microalbuminuria (IRMA 2) substudy
por: Broedbaek, Kasper, et al.
Publicado: (2011)

Experiencia clínica de Irbesartán a lo largo del espectro de la enfermedad cardiovascular : ampliando evidencia con Irbesartan
Publicado: (2007)

Determinants of persistence in hypertensive patients treated with irbesartan: results of a postmarketing survey
por: Burnier, Michel, et al.
Publicado: (2005)

A validated stability indicating HPTLC method for simultaneous estimation of irbesartan and hydrochlorothiazide
por: Khodke, Amol S, et al.
Publicado: (2010)

Action of irbesartan on blood pressure and glucose/lipid metabolism, in hemodialysis patients with hypertension
por: Onishi, Akira, et al.
Publicado: (2013)

Irbesartan prevents sodium channel remodeling in a canine model of atrial fibrillation
por: Wang, Xuewen, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_t5kjb0slt7fs76dk36hnt96cn7